Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab IV in Active RA Despite MTX (GO-LIVE)
NCT00361335Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2006
- Primary completion
- Dec 2007
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of golimumab in rheumatoid arthritis (RA), sponsored by Janssen Pharmaceutical. Primary endpoint: American College of Rheumatology 50 Response at 14 weeks. Started Sep 2006; status: completed.
02
Drugs
golimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00361335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00361335.